Quest Partners LLC Purchases 36,652 Shares of Catalent, Inc. (NYSE:CTLT)

Quest Partners LLC raised its holdings in Catalent, Inc. (NYSE:CTLT) by 289.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 49,300 shares of the company’s stock after acquiring an additional 36,652 shares during the quarter. Quest Partners LLC’s holdings in Catalent were worth $2,986,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Gamco Investors INC. ET AL raised its position in shares of Catalent by 403.3% in the 1st quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company’s stock worth $1,428,000 after acquiring an additional 20,273 shares in the last quarter. UniSuper Management Pty Ltd grew its position in Catalent by 509.4% in the 1st quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company’s stock worth $1,028,000 after purchasing an additional 15,217 shares in the last quarter. Swedbank AB bought a new position in shares of Catalent in the first quarter valued at approximately $1,659,000. New York Life Investment Management LLC grew its stake in Catalent by 67.9% in the 2nd quarter. New York Life Investment Management LLC now owns 297,903 shares of the company’s stock valued at $16,751,000 after purchasing an additional 120,502 shares during the period. Finally, Vanguard Group Inc. grew its position in Catalent by 1.1% during the first quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock valued at $1,151,872,000 after buying an additional 218,682 shares during the period.

Insider Activity at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock worth $305,931 in the last ninety days. 0.31% of the stock is owned by company insiders.

Catalent Price Performance

Shares of Catalent stock opened at $59.10 on Monday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. Catalent, Inc. has a 52-week low of $36.74 and a 52-week high of $61.20. The company has a fifty day moving average of $59.84 and a 200-day moving average of $58.21. The stock has a market capitalization of $10.73 billion, a price-to-earnings ratio of -26.15, a price-to-earnings-growth ratio of 2.35 and a beta of 1.16.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.10) earnings per share. Equities research analysts expect that Catalent, Inc. will post 0.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on CTLT shares. StockNews.com raised Catalent from a “sell” rating to a “hold” rating in a research report on Thursday. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Eight analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.